Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Post-residency career intentions among oncology and related specialty residents in Armenia.

Sergey Badalyan, Nune Karapetyan, Amalya Sargsyan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21012

e21012 Background: In Armenia, postgraduate training for Medical, Radiation, and Surgical oncology is delivered through a...

Effect of an EHR-facilitated symptom surveillance intervention on rehabilitation utilization in cancer patients.

Toure Barksdale, Subha Hanif, Jeph Herrin et al. Jun 01, 2026 pp. 1587-1587 10.1200/jco.2026.44.16_suppl.1587

1587 Background: Rehabilitation services (physical medicine and rehabilitation [PM&R], physical therapy [PT], occupati...

Allostatic load and myosteatosis in women with metastatic breast cancer at diagnosis.

Avery Hensel, Emma Kortmansky, Sandra L. Gomez Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13018

e13018 Background: llostatic load (AL), a measure of cumulative physiological stress, and myosteatosis, fatty infiltration...

Early versus delayed initiation of first-line immune checkpoint inhibitors in metastatic non–small cell lung cancer: A real-world analysis of treatment timing and care context.

Nandhini Iyer, Ansy Patel, Deevyashali Parekh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20660

e20660 Background: Immune checkpoint inhibitors (ICIs) are standard first-line therapy for metastatic non–small cell lung...

A machine learning algorithm for optimizing treatment selection for patients with up to three hepatocellular carcinomas measuring ≤ 3 cm.

Takashi Kokudo, Yasuhide Yamada, Yoshinari Asaoka et al. Jun 01, 2026 pp. 4019-4019 10.1200/jco.2026.44.16_suppl.4019

4019 Background: Liver resection (LR) and radiofrequency ablation (RFA) are recommended for patients with early-stage hepa...

Phase II study evaluating ivonescimab in combination with chemotherapy as first- and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients (UCGI 52 – GRACIE).

Christelle de la Fouchardière, Sophie Gourgou, Clélia Coutzac et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps4239

TPS4239 Background: The prognosis of advanced/metastatic gastroesophageal adenocarcinomas (GEA) has recently improved with...

Impact of metformin on outcomes with immune checkpoint inhibitors in renal cell carcinoma: A large-scale retrospective analysis.

Harshitha Chowdary Popuri, Mariah Black, Mostafa Eysha et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16558

e16558 Background: Immune checkpoint inhibitors (ICIs) are a mainstay in the treatment of renal cell carcinoma (RCC). Metf...

A validation study of a novel biomarker-based scoring system (EAST score) for limited-stage small-cell lung cancer: A secondary analysis of JCOG0202 and JCOG1011.

Yu Ito, Yoshitaka Zenke, Noriko Mitome et al. Jun 01, 2026 pp. 8081-8081 10.1200/jco.2026.44.16_suppl.8081

8081 Background: Concurrent chemoradiotherapy (CCRT) followed by prophylactic cranial irradiation (PCI) is potentially cur...

SPARTO: A phase I study of PD-1 inhibitor spartalizumab (PDR001) in combination with low dose of pazopanib in pediatric relapsed/refractory tumors.

Jordane Chaix, Eric Frison, Birgit Geoerger et al. Jun 01, 2026 pp. 10001-10001 10.1200/jco.2026.44.16_suppl.10001

10001 Background: The initial results of immunotherapy in children with refractory/relapsed tumors have been disappointing...

Timing of palliative care referral and overall survival in patients with melanoma brain metastases treated with ipilimumab and nivolumab.

Joseph Brandon Parker, Dina Elantably, Jakob Skyler Hamilton et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21607

e21607 Background: The association between timing of palliative care referral and survival outcomes in patients with melan...

Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial.

Jose Lucinio Mondaza-Hernandez, David Silva Moura, Andres Redondo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23520

e23520 Background: Solitary fibrous tumor (SFT) is a rare sarcoma subtype characterized by limited therapeutic options in...

Efficacy and safety of cadonilimab in patients with MSI-H/dMMR locally advanced or metastatic gastrointestinal malignancies: A real-world retrospective study.

Xiaoyuan Sun, Zimin Liu, Yandong Ci Jun 01, 2026 pp. 2623-2623 10.1200/jco.2026.44.16_suppl.2623

2623 Background: Immunotherapies targeting PD-1 and CTLA-4 have emerged as promising therapeutic strategies for gastrointe...

Risk of developing brain/central nervous system (CNS) metastases across multiple <i>ERBB2</i> -altered cancer types: Genotype as shaper of phenotype.

Aditya V. Shreenivas, Gerald Li, Anikó Szabó et al. Jun 01, 2026 pp. 2022-2022 10.1200/jco.2026.44.16_suppl.2022

2022 Background: ERBB2 (HER2) alterations are associated with increased risk of brain metastases in br...

High-quality 4D anatomical and functional MRI for abdominal tumor motion management.

Junjie Ma, Wenbin Gao, Jian Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16013

e16013 Background: 4D-MRI offers superior soft-tissue contrast for abdominal motion management but is often limited by the...

Association between clonal plasma cell S-phase after autologous stem cell transplantation and survival outcomes in multiple myeloma.

Tamer Hellou, Daniel G. Packard, Maximilian J. Steinhardt et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19564

e19564 Background: Risk stratification in multiple myeloma (MM) relies on baseline staging systems and cytogenetic abnorma...

Global variation in thromboprophylaxis models of care and implementation supports for hospitalized and ambulatory cancer care.

Kellie Weddle, Hadley Bortz, Julianne Chong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13627

e13627 Background: Cancer-associated thrombosis (CAT) is a leading cause of morbidity and mortality. As systemic therapies...

Burden and temporal trends of pediatric central nervous system tumors in Kenya: A 15-year analysis from a national referral hospital.

Philip Maseghe Mwachaka, Scott L. Coven, Minda Maseghe Okemwa Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14045

e14045 Background: Pediatric central nervous system (CNS) tumors are a leading cause of childhood cancer mortality globall...

How long is long enough? Outcomes with finite-duration bispecific antibody therapy in multiple myeloma.

Eva Duvalyan, Jihong Song, Samantha Shenoy et al. Jun 01, 2026 pp. 7538-7538 10.1200/jco.2026.44.16_suppl.7538

7538 Background: Bispecific antibodies (BsAbs) have shown unprecedented efficacy in relapsed/refractory multiple myeloma (...

Determinants of survival in 356 patients failing frontline HMA-Ven for newly-diagnosed AML.

Mahnoor Fatima, Sudhesh Kumar, Momna Warraich et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18524

e18524 Background: Venetoclax (Ven) in combination with hypomethylating agents (HMA) is FDA-approved front-line therapy fo...

First-line HLX07 vs placebo combined with serplulimab and chemotherapy for nasopharyngeal carcinoma: A randomized, double-blind, multicenter phase 2 study.

Wenfeng Fang, Xiaohong Ai, Feng Lei et al. Jun 01, 2026 pp. 6042-6042 10.1200/jco.2026.44.16_suppl.6042

6042 Background: Programmed cell death protein 1 (PD-1) blockade with chemotherapy confers significant survival benefit co...

A multicenter pilot study of afatinib re-challenge in patients with <i>EGFR</i> -mutated non-squamous non–small cell lung cancer previously treated with osimertinib.

Taisuke Araki, Ryo Ichikawa, Akane Kato et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20748

e20748 Background: Osimertinib (+ chemotherapy) is the standard first-line treatment for EGFR...

Comprehensive genomic profiling to identify molecular determinants of efficacy of IDH1 inhibition in intrahepatic cholangiocarcinoma.

Sunyoung S. Lee, Nikolas Naleid, Dong Hyun Seo et al. Jun 01, 2026 pp. 4147-4147 10.1200/jco.2026.44.16_suppl.4147

4147 Background: Ivosidenib (IVO) in IDH1 -mutant iCCA yields modest mPFS (2.7 m)...

Construction of an in-vitro peritoneal metastasis model and evaluating its feasibility for experimental peritoneal metastasis research.

Carolina Khosrawipour, Hien Lau, Agata Mikolajczyk-Martinez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15527

e15527 Background: Currently, a wide range of therapeutic strategies are studied and developed for the treatment of perito...

Immune effector cell–associated enterocolitis (IEC-EC) incidence and characterization in cilta-cel–treated patients with RRMM in CARTITUDE clinical studies.

Yi Lin, Shaozhou Ken Tian, Elizabeth Montgomery et al. Jun 01, 2026 pp. 7533-7533 10.1200/jco.2026.44.16_suppl.7533

7533 Background: Ciltacabtagene autoleucel (cilta-cel) shows benefit for patients (pts) with relapsed/refractory multiple...

Stage-specific associations between clinical, demographic, and treatment factors and long-term survival in ovarian cancer.

Daniel Moncada, Heidi David, Karen Asher et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17610

e17610 Background: Ovarian cancer remains the deadliest gynecologic malignancy, largely due to advanced-stage presentation...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page